Plasma level median (IQR) | Control (n = 10) | Survivor patients (n = 6) | Non-survivor patients (n = 11) | ||
---|---|---|---|---|---|
D0 | D7 | D0 | D7 | ||
Total cholesterol (mg/dL) | 198 | 90.5* | 110.5* | 105* | 104* |
 | (176.5–245.5) | (79–121.5) | (103–145.5) | (86–125) | (91–150) |
HDL-C (mg/dL) | 54.5 | 20* | 33.5* | 23* | 20* |
 | (45.8–59.3) | (7.8–33.5) | (17.8–42.5) | (21–35) | (12–48) |
LDL-C (mg/dL) | 121.5 | 51* | 68* | 56* | 59* |
 | (89–161.3) | (39.8–79) | (56.3–80) | (52–68) | (52–83) |
Non-HDL-C (mg/dL) | 148 | 70* | 86* | 79* | 86* |
 | (121.8–190.3) | (54–99.5) | (70–109.3) | (72–97) | (77–103) |
Triglycerides (mg/dL) | 144 | 89.5 | 103 | 125 | 127 |
 | (115–184.5) | (64.5–165.3) | (67.5–200) | (85–179) | (106–177) |
APO A-I (mg/dL) | 151.5 | 65* | 92* | 67* | 67* |
 | (139.8–177.5) | (45.8–88.3) | (58.8–109.8) | (63–88) | (49–91) |
APO B (mg/dL) | 104 | 56.5* | 72.5* | 71* | 77 |
 | (85.5–141.5) | (50.5–73) | (68.3–78.5) | (48–86) | (71–112) |
Lipoproteins (mg/dL) | 15.5 | 5.8 | 5.9 | 6.5 | 13.2 |
 | (8.6–26.9) | (3.27–25) | (4.12–31.6) | (4.9–14.9) | (5.8–36.8) |
PON 1 (ng/mL)# | 210.2 | 106.3* | 111.9* | 110.2* | 113.8* |
 | (170.1–313.7) | (78.9–141.5) | (83.6–189.4) | (93.5–183.6) | (98.5–174.9) |
Haptoglobin (mg/mL)# | 0.98 | 1.6 | 1.4 | 1.3 | 1.5 |
 | (0.7–1.3) | (0.9–2.1) | (0.8–1.7) | (0.9–1.7) | (1.2–1.6) |